Promising European Penny Stocks To Consider In September 2026

As European markets navigate the challenges of rising oil prices and inflation concerns, investors are keenly observing opportunities that might arise in this shifting landscape. Penny stocks, often associated with smaller or newer companies, offer a unique blend of affordability and potential growth. Despite their vintage label, these stocks can still present valuable prospects when backed by strong financials and solid fundamentals.

Let's dive into some prime choices out of the screener.

Vidhance (DB:8W50)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Vidhance AB (publ) is a company based in Sweden that offers AI-powered software solutions, with a market cap of €28.30 million.

Operations: The company generates its revenue from the Software & Programming segment, amounting to SEK 15.25 million.

Market Cap: €28.3M

Vidhance AB, with a market cap of €28.30 million, operates in the AI-powered software solutions sector but remains unprofitable with declining revenues. Recent earnings reports indicate sales of SEK 7.36 million for the first half of 2026, down from SEK 10.1 million a year ago, and a net loss of SEK 11.63 million compared to SEK 14.36 million previously. The company is debt-free but faces challenges such as high volatility and limited cash runway under one year if free cash flow continues to decline at historical rates. Despite no significant shareholder dilution recently, profitability remains elusive.

• Click to explore a detailed breakdown of our findings in Vidhance's financial health report.
• Explore historical data to track Vidhance's performance over time in our past results report.

Redsense Medical (DB:R0Z)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Redsense Medical AB (publ) offers a blood leakage alarm system for monitoring hemodialysis treatments across Europe, Canada, and Australia, with a market cap of €57.56 million.

Operations: The company generates revenue from its Patient Monitoring Equipment segment, totaling SEK 29.24 million.

Market Cap: €57.56M

Redsense Medical AB, with a market cap of €57.56 million, has shown some financial improvement recently, reporting a net income of SEK 1.54 million for the first half of 2026 compared to a loss last year. Despite these gains, the company remains unprofitable overall and faces high share price volatility. It is debt-free but has less than one year of cash runway based on current free cash flow levels. The management team is experienced with an average tenure of 2.7 years, and no significant shareholder dilution occurred in the past year. Redsense's new digital training platform aims to enhance product usage consistency across markets.

• Dive into the specifics of Redsense Medical here with our thorough balance sheet health report.
• Review our historical performance report to gain insights into Redsense Medical's track record.

Safello Group (OM:SFL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Safello Group AB (publ) operates a brokerage platform catering to individuals and businesses, with a market cap of SEK63.19 million.

Operations: The company generates its revenue primarily through its brokerage segment, which accounted for SEK711.49 million.

Market Cap: SEK63.19M

Safello Group AB, with a market cap of SEK63.19 million, operates in the brokerage sector but remains unprofitable, reporting a net loss of SEK7.32 million for Q2 2026. The company has reduced losses over five years by 18.8% annually and is debt-free, though it faces less than one year of cash runway based on free cash flow trends. While its board boasts an average tenure of 13.7 years indicating experience, the management team is relatively new with an average tenure of 1.1 years. Share price volatility remains high compared to most Swedish stocks.

• Click here and access our complete financial health analysis report to understand the dynamics of Safello Group.
• Gain insights into Safello Group's past trends and performance with our report on the company's historical track record.

Make It Happen

• Embark on your investment journey to our 308 European Penny Stocks selection here.
• Ready To Venture Into Other Investment Styles? The end of cancer? These 34 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com